Helicobacter pylori - Negative duodenal ulcers: Prevalence, clinical characteristics, and prognosis - Results from a randomized trial with 2-year follow-up

American Journal of Gastroenterology

Volumn 96, Issue 5, 2001, Pages 1409-1416

  Bytzer, Peter ^a   Teglbjærg, Peter Stubbe ^a,b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STOMACH EMPTYING;

EID: 0342502233     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02337-1     Document Type: Article

References (27)

1. Massuda H.K., Boyd E.J.S. Who should undergo testing for Helicobacter pylori? Am J Gastroenterol. 91:1996;1070-1071.
2. Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut. 34:1993;1672-1676.
3. Helicobacter pylori in peptic ulcer disease. JAMA. 272:1994;65-69.
4. Gisbert J.P., Blanco M., Mateos J.M., et al. H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci. 44:1999;2295-2302.
5. Ciociola A.A., McSorley D.J., Turner K., et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol. 94:1999;1834-1840.
6. Henry A., Batey R.G. Low prevalence of Helicobacter pylori in an Australian duodenal ulcer population NSAIDitis or the effect of ten years of H. pylori treatment? Aust NZ J Med. 28:1998;345.
7. Sprung D.J., Apter M., Allen B., et al. The prevalence of Helicobacter pylori in duodenal ulcer disease - a community based study. Am J Gastroenterol. 91:1996;1926.
8. Xia H.H.X., Phung N., Kalandar J., et al. Characteristics of Helicobacter pylori positive and negative peptic ulcer disease. Gastroenterology. 116:1999;A359.
9. Jyotheeswaran S., Shah A.N., Jin H.O., et al. Prevalence of Helicobacter pylori in peptic ulcer patients in Great Rochester, NY Is empirical triple therapy justified? Am J Gastroenterol. 93:1998;574-578.
10. Tovey F.I., Hobsley M. Is Helicobacter pylori the primary cause of duodenal ulceration? J Gastroenterol Hepatol. 14:1999;1053-1056.
11. Bytzer J.P., Aalykke C., Rune S., et al. Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomised trial with 2 years follow-up. Scand J Gastroenterol. 35:2000;1023-1032.
12. Guidelines for clinical trials in Helicobacter pylon infection. Gut. 41:(suppl 2):1997;S1-S23.
13. Kjøller M., Fischer A., Justesen T. Transport conditions and number of biopsies necessary for culture of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 10:1991;166-167.
14. Andersen L.P., Holck S., Povlsen C.O., et al. Gastric and duodenal infection caused by C. pyloridis Histopathologic and microbiologic findings . Scand J Gastroenterol. 22:1987;219-224.
15. Vyberg M., Nielsen S. Dextran polymer conjugate two-step visualization system for histochemistry. A comparison of EnVision+ with two three-step avidin-biotin techniques. Appl Immunohistochem. 6:1998;3-10.
16. Cutler A.F. Testing for Helicobacter pylori in clinical practice. Am J Med. 100:1996;35S-41S.
17. Freston J.W. Helicobacter pylori-negatiye peptic ulcers Frequency and implications for management . J Gastroenterol. 35:(suppl 12):2000;29-32.
18. McColl K.E. Helicobacter pylori-negative ulcer disease. J Gastroenterol. 35:(suppl 12):2000;47-50.
19. Gillen D., Wirz A., Neithercut W.D., et al. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut. 44:1999;468-475.
20. Verdu E.F., Armstrong D., Idström J-P., et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut. 37:1995;743-748.
21. Tsuji H., Kohli Y., Fukumitsu S., et al. Helicobacter pylori-negative gastric and duodenal ulcers. J Gastroenterol. 34:1999;455-460.
22. Hyvarinen H., Salmenkyla S., Sipponen P. Helicobacter pylori-negative duodenal and pyloric ulcer Role of NSAIDs . Digestion. 57:1996;305-309.
23. Higuchi K., Arakawa T., Fujiwara Y. Is Helicobacter pylori-negative duodenal ulcer masked by the high prevalence of H. pylori infection in the general population? Am J Gastroenterol. 94:1999;3083-3084.
24. Kurata J.H., Nogawa A.N. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal inflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 24:1997;2-17.
25. Lane L., Hopkins R.J., Girardi L.S. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol. 93:1998;1409-1415.
26. Talley N.J., Axon A., Bytzer P., et al. Management of uninvestigated and functional dyspepsia A working party report for the World Congresses of Gastroenterology . Aliment Pharmacol Ther. 13:1999;1135-1148.
27. Lassen A.T., Pedersen F.M., Bytzer P., et al. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients A randomised trial . Lancet. 356:2000;455-460.